PureLife, LLC
$214.1K 2,242 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Planmeca USA, Inc.
Planmeca USA, Inc. reported $214,156.53 across General Payments, Research, and Ownership to 226 physicians and teaching hospitals across 226 transactions.
- $214.2K Below-median payer
- All-tracks total
- 226 Above-median volume
- Transactions
- 226 Above-median reach
- Recipients
- −$28.0K
- General Payments vs PY2023
Planmeca USA, Inc. reported $214,156.53 across all CMS Open Payments tracks (General + Research + Ownership) to 226 physicians and teaching hospitals in Program Year 2024 - ranking #981 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $214,156.53, averaging $947.60 per recipient.
Planmeca USA, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
22/100
Total payments
F
12/100
Transaction volume
F
12/100
Physician reach
F
12/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer planmeca-usa-inc Planmeca USA, Inc.
$214.2K · #981/1,925 · 0.0% industry · PY2024
- TOT $214.2K
- RANK #981
- SHARE 0.0%
- TXN 226
- RCP 226
- CAT 4
- GEN $214.2K
- ΔGEN −$28.0K
- TOP1 18.0%
- PY 2024
Volume peers
Nearest volume peer: PureLife, LLC ($214.1K)
Planmeca USA, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Planmeca USA, Inc.'s CMS-reported General Payments decreased by $28.0K (−11.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PLANMECA USA, INC.PY2023: PLANMECA USA, INC.PY2024: Planmeca USA, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $242,149.44
- PY2024
- $214,156.53
What the Data Shows for Planmeca USA, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Planmeca USA, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
Of the 4 general-payment categories charted below, "Honoraria" is the largest at $111.9K across 29 transactions, 52.2% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Planmeca USA, Inc. made 4 types of general payments. "Honoraria" is the largest category at $111.9K, 52.2% of General Payments.
Planmeca USA, Inc. reports 4 general-payment categories - the top three are Honoraria (52.2%), Compensation for Services Other Than Consulting (35.3%), and Food and Beverage (6.3%). The remaining 1 category make up 6.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Planmeca USA, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $111.9K | 29 | 52.2% |
| Compensation for Services Other Than Consulting | $75.6K | 17 | 35.3% |
| Food and Beverage | $13.5K | 133 | 6.3% |
| Travel and Lodging | $13.2K | 47 | 6.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $114,980.38 (53.7%) of $214,156.53 in this company's General Payments records across 107 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Planmeca USA, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Peter Green
$38,587.25 across 44 reported transactions
- 2
Zachary Evans
$22,967.72 across 20 reported transactions
- 3
Shea Mathew Tolbert
$22,371.58 across 11 reported transactions
- 4
Jesse D Clark
$15,699.50 across 14 reported transactions
- 5
Walter Renne
$15,354.33 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Planmeca USA, Inc.'s spend rank (#981 of 1,925, bottom 49% by spend) and concentration rank (#1,112 of 1,838, bottom 40% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Day One Biopharmaceuticals : $191.7K total payments, HHI 822
- Altus Partners. LLC : $374.7K total payments, HHI 817
- SIGN Fracture Care International : $6.8K total payments, HHI 815
- Septodont Inc. : $289.4K total payments, HHI 813
- BioHorizons Implant Systems Inc. : $1.4M total payments, HHI 813
- PTC Therapeutics, Inc. : $464.2K total payments, HHI 811
- Planmeca USA, Inc. (this company) : $214.2K total payments, HHI 810
- Elevation Spine, Inc. : $38.6K total payments, HHI 810
- Terumo Cardiovascular Systems Corporation : $22.7K total payments, HHI 809
- Pierre Fabre Pharmaceuticals, Inc. : $53.6K total payments, HHI 809
- Marinus Pharmaceuticals, Inc. : $279.2K total payments, HHI 807
- 3B Medical, Inc. : $29.3K total payments, HHI 805
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Planmeca USA, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Planmeca USA, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Planmeca USA, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
LEO Pharma AS
$214.7K 200 recipients
Compare payment profiles
Fennec Pharmaceuticals, Inc.
$215.0K 1,115 recipients
Compare payment profiles
Acarix USA Inc.
$215.3K 83 recipients
Compare payment profiles
Mohawk Hospital Equipment, Inc.
$212.0K 4 recipients
Compare payment profiles
Surgical Specialties Corporation (us), Inc. (dba Corza Medical)
$210.1K 577 recipients
Compare payment profiles
Put this to use
Planmeca USA, Inc. ranks #981 of 1,925 by all-tracks total payments, led by "Honoraria".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just Planmeca USA, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.